PT  - JOURNAL ARTICLE
AU  - Menghrajani, Kamal
AU  - Dilip, Deepika
AU  - Farnoud, Noushin
AU  - Famulare, Chris
AU  - McGovern, Erin
AU  - Sirenko, Maria
AU  - Mascarenhas, John
AU  - Kosiorek, Heidi
AU  - Hoffman, Ronald
AU  - Levine, Ross
AU  - Koche, Richard
AU  - Rampal, Raajit
AU  - Glass, Jacob
TI  - MPN Transformation Is Characterized By Heterogeneous Shifts In Lineage Character Resulting In Both HSC-Like And More Differentiated Lineage Signatures
AID  - 10.1101/2024.04.16.24305909
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.04.16.24305909
4099  - http://medrxiv.org/content/early/2024/04/19/2024.04.16.24305909.short
4100  - http://medrxiv.org/content/early/2024/04/19/2024.04.16.24305909.full
AB  - Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) have a propensity to transform to an accelerated or blast phase (MPN-AP/BP). The resulting disease has clinically similar manifestations to Acute Myeloid Leukemia (AML) but worse clinical outcomes. Here we present the first comprehensive description of the transcriptomic characteristics of MPN-AP/BP. Our analysis incorporates data from 261 patients of the BeatAML cohort and 56 MPN-AP/BP patients, 11 of whom had paired samples from before and after transformation. We establish that transformed MPN is a transcriptionally distinct entity from de novo AML and chronic phase MPNs. Genomic pathways traditionally associated with MPN pathogenesis, such as IL2/STAT5 signaling, IL6/JAK/STAT3 signaling, and NUP98/HOXA9 fusions, were enriched in chronic-phase MPNs but are absent in transformed disease, suggesting JAK2 directed therapy may be less effective in this disease phase. We also discovered that gene expression signatures associated with doxorubicin resistance are highly enriched in transformed MPNs, which may explain the lack of efficacy of standard AML therapies. In addition, we identify that lineage composition at the time of transformation may define distinct subsets of MPN-AP/BP patients, which may assist in the future development of novel treatment strategies.Key Points- Accelerated- and blast-phase transformed MPNs are a transcriptionally entities which are distinct from de novo AML.- Transformed MPNs may be characterized by their lineage characteristics, which can drive clinical behavior and account for their inferior overall survival- Gene expression signatures associated with doxorubicin resistance were highly enriched in transformed MPNs, which may explain the lack of effectiveness of anthracycline-based therapiesCompeting Interest StatementThe authors have declared no competing interest.Funding StatementNIH 5K08CA230172 Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Memorial Sloan Kettering Cancer Center gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE210253